Compare Adaptive Biotechnologies Corp (ADPT) vs Schwab US Dividend Equity ETF (SCHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Schwab US Dividend Equity ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Schwab US Dividend Equity ETF trades at $34.28. Which is the better fit depends on your goals.
| ADPT | SCHD | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $25.45 | $34.27 |
52-Week Low | $12.30 | $26.44 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
SCHD trades at $34.26, showing modest daily gains of 0.2% with strong bullish technical signals from moving averages. The ETF maintains its position as a core dividend equity holding, though key valuation metrics remain unavailable in current data. Recent institutional activity shows Barry Investment Advisors increased their position by 29.9% during Q2 2026, indicating continued institutional confidence in the fund's strategy.
SCHD faces competition from alternative income ETFs while benefiting from the current market rotation toward value strategies. The fund's 2% yield and dividend-focused approach appeal to retirement investors, though tax efficiency considerations remain crucial for optimal positioning. Market sentiment suggests SCHD serves as a defensive holding in volatile environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Schwab US Dividend Equity ETF
SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →
